Life Biosciences

Extracted Attributes

• CEO

  Jerry McLaughlin

• COO

  Michael Ringel

• Founded

  2017-01-01

• Founder

  David Sinclair

• Industry

  Biotechnology

• Headquarters

  Boston, Massachusetts, USA

• Core Technology

  Partial Epigenetic Reprogramming (Yamanaka factors)

• Lead Therapeutic Program

  ER-100

Timeline

• Life Biosciences was founded to develop cellular rejuvenation therapies. (Source: Wikidata)

  2017-01-01

• Signed a Memorandum of Understanding (MOU) with REMEDIS in Singapore to advance scientific capabilities in regenerative medicine. (Source: Life Bio Press Release)

  2025-07-22

• Announced securing FDA approval for Phase 1 human clinical trials to treat blindness using epigenetic reprogramming. (Source: Fortune)

  2026-01-28

• Target date for the lead program ER-100 to enter clinical trials for glaucoma and NAION indications. (Source: Life Bio Press Release)

  2026-03-31

List of life sciences

This list of life sciences comprises the branches of science that involve the scientific study of life — such as animals (including human beings), microorganisms, and plants. This is one of the two major branches of natural science, the other being physical science, which is concerned with non-living matter. Biology is the overall natural science that studies life, with the other life sciences as its sub-disciplines. Some life sciences focus on a specific type of organism. For example, zoology is the study of animals, while botany is the study of plants. Other life sciences focus on aspects common to all or many life forms, such as anatomy and genetics. Some focus on the micro scale (e.g., molecular biology, biochemistry), while others focus on larger scales (e.g., cytology, immunology, ethology, pharmacy, ecology). Another major branch of life sciences involves understanding the mind—neuroscience. Life-science discoveries are helpful in improving the quality and standard of life and have applications in health, agriculture, medicine, and the pharmaceutical and food science industries. For example, they have provided information on certain diseases, which has helped in the understanding of human health.

Web Search Results

• Life Bio - Research Collaboration with REMEDIS in Singapore

  About Life Biosciences Life Bio is a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. The company’s proprietary Partial Epigenetic Reprogramming platform utilizes three transcription factors—Oct4, Sox2, and Klf4—to restore older and damaged cells to a younger state. This innovative approach targets a root cause of aging at the epigenetic level, thereby offering the potential to address a wide range of serious age-related diseases. Life Bio’s lead program, ER-100, is being developed for optic neuropathies, including glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), with plans to enter the clinic in the first quarter of 2026 for both indications. Beyond ER-100, the company is strategically broadening its [...] BOSTON, July 22, 2025 – Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced the signing of a Memorandum of Understanding (MOU) with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (“REMEDIS”), a joint research institute under the auspices of the SingHealth Duke-NUS Academic Medical Centre, to continue to build out its therapeutic portfolio. The REMEDIS collaboration will enhance Life Bio’s growing R&D efforts to advance its cellular rejuvenation technology across age-related diseases by targeting multiple organ systems and will also continue to accelerate scientific capabilities in Singapore. [...] Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential. For more information, visit www.lifebiosciences.com or follow Life Bio on Twitter (X) and LinkedIn.

• About Life Biosciences

  We are pursuing a platform approach to develop therapeutics that can reverse and prevent multiple age-related conditions. Our platforms are based on groundbreaking science from world-class researchers. We have exclusive licenses with leading academic institutions underpinned by strong composition-of-matter and method-of-use patents. Life Biosciences is headquartered in Boston, MA. #### The Opportunity 80% of those over 60 years of age have at least one chronic illness, 50% have two or more 30% of people ages 65 or older in OECD (Organization for Economic Cooperation and Development) countries need assistance with activities of daily living The proportion of the world’s population over 60 years of age will nearly double from 12% in 2015 to 22% in 2050

• Life Biosciences

  excited about that data.” Read the full article here: [Likes: 71, Comments: 3] [...] Regenerative Medicine Institute of Singapore (REMEDIS) , a partnership designed to utilize our partial epigenetic reprogramming platform to accelerate the translation of cellular rejuvenation science into therapies that extend healthy lifespan. Read more: [Likes: 44, Comments: 1]; Life Biosciences (2mo Edited): Our CEO, Jerry McLaughlin , will join globally recognized neurologist, Dr. Bartlomiej Piechowski-Jozwiak , for a fireside chat at the 2025 GITEX GLOBAL Largest Tech & Startup Show in the World in Dubai, UAE. Together, they’ll discuss how advancements in longevity science are extending healthspan by adding more healthy, productive years to life, rather than simply prolonging it. The conversation will also explore the global and societal impacts of these innovations and what they [...] and societal impacts of these innovations and what they mean for living a full, purposeful life. For conference information, visit: [Likes: 62, Comments: 0]; Michael Ringel (2mo): Is interest in #longevity #biopharma increasing? If so, by how much? In this definitive report in Nature Aging, Wen Kin Lim , Yue Zhang of Boston Consulting Group (BCG) BCG on Health Care quantify across metrics the increasing activity in human therapeutics that work by pathways of #aging biology. Soon, Life Biosciences will be the first company to start clinical trials on a cellular rejuvenation therapy, starting in #glaucoma and #NAION but with data already released on #metabolic #liver disease as well. Link: [Likes: 87, Comments: 2]; Life Biosciences (2mo): Our COO, Michael Ringel , JD, PhD, will be

• Management Team – Life Biosciences, Inc.

  having led global translational alliances and has a strong publication and patent record. A key focus for Sharon is building high-quality, integrated, cross-functional teams utilizing both internal and external talent to deliver programs in a timely manner employing evidence-based decision making. She earned her BA in biological basis of behavior from the University of Pennsylvania and her PhD in psychology (behavioral neuroscience) from Harvard University. [...] commercialization and acquisition in the US and Europe. Michel has a PhD in organic chemistry from Avignon University, France and completed his postdoctoral fellowship at Duke University working on biomaterials in the Department of Chemistry. [...] Dr. Michel Wathier is senior vice president of chemistry manufacturing and control (CMC). With more than 20 years of experience leading the formulation development and manufacture of complex drugs, Michel has a deep understanding and expertise in CMC program management, operation, and regulatory. His experiences encompass devices, small and large molecules, combination products, and new modalities. Michel has experience with regulatory environments in both the United States and internationally and has led 15 compounds through successful IND filings; he co-authored 20 patents and effectively moved numerous products from R&D to human clinical studies. His development work on devices led to Adherus and OcuSeal and their successful commercialization and acquisition in the US and Europe.

• This startup has the lead in longevity, securing the first FDA ...

  Life Biosciences, a biotech company cofounded by Harvard genetics professor David Sinclair, said Wednesday it had secured approval for a Phase 1 clinical trial aiming, in part, to restore vision in people with eye conditions such as glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION) through “partial epigenetic reprogramming.” During the trial, researchers will attempt to turn back the biological clock on damaged cells in a person’s eye by directly injecting it. This allows the therapy to reach damaged retinal ganglion cells and deliver “rejuvenation instructions” directly to the target cells to help restore their function and potentially reverse vision loss. [...] ## The science behind Life Biosciences Life Biosciences cofounder and Harvard geneticist Sinclair is the key behind the company’s FDA breakthrough. Previously Sinclair, who earned a Ph.D. in molecular genetics from the University of New South Wales, led pioneering research on partial epigenetic reprogramming, partially de-aging cells by modifying their epigenome, biochemical markers that tell genes when to turn on or off without altering the underlying DNA sequence. [...] “The bad news is there’s absolutely nothing to treat [NAION], and the even worse news is that there’s about a 20-to-30% chance in the next two to three years it’s going to happen in the second eye,” he said. McLaughlin said Life Biosciences is already applying its epigenetic reprogramming to help treat other conditions. The company previously saw success in treating liver fibrosis, or MASH, which he said showed the company’s approach “transcends organs.” While the company is first focused on helping patients with vision loss, McLaughlin isn’t ignorant about the potentially giant opportunity opening up thanks to a rapidly aging global population.

• Instance Of

  Q168678

• Inception Date

  1/1/2017